The genetic association between nonalcoholic fatty liver disease and type 2 diabetes mellitus in different body mass index categories： A bidirectional Mendelian randomization study

Haoxin DUAN; Yuyong JIANG; Tingyu WU; Feixiang XIONG; Yandan JIANG; Qin ZHANG; Saisai ZHAO; Hao YU

doi:10.12449/JCH241011

Volume 40 Issue 10

Oct. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(10): 1992-1999

PDF( 3023 KB)

The genetic association between nonalcoholic fatty liver disease and type 2 diabetes mellitus in different body mass index categories： A bidirectional Mendelian randomization study

DOI: 10.12449/JCH241011

1.
Graduate School，Dongzhimen Hospital，Beijing University of Chinese Medicine，Beijing 100700，China
2.
Department of Integrative Medicine，Beijing Ditan Hospital，Capital Medical University，Beijing 100015，China

Research funding:

Beijing Municipal High Rank Public Health Researcher Training Program (Discipline Leader-03-04);

Capital Health Research and Development Project (2020-2-2172)

More Information

Corresponding author: YU Hao， yuhaodtyy@126.com （ORCID： 0000-0002-2213-0725）
Received Date: 2024-06-04
Accepted Date: 2024-07-25
Published Date: 2024-10-25

Abstract

Abstract

Objective To investigate the genetic association between nonalcoholic fatty liver disease （NAFLD） and type 2 diabetes mellitus （T2DM） using bidirectional two-sample Mendelian randomization （MR）， as well as the causal relationship between NAFLD and T2DM across different body mass index （BMI） categories. Methods The data were derived from genome-wide association studies conducted in European populations， with a sample size of 32 941 cases for NAFLD， 312 646 cases for T2DM， and 681 275 cases for BMI. The univariate and multivariate MR methods were used to assess the bidirectional causal relationship between NAFLD and T2DM in the general population and across different BMI subtypes. The methods of inverse-variance weighting， MR-Egger regression， constrained maximum likelihood and model averaging， and weighted median were used to conduct the MR analysis， and MR-Pleiotropy Residual Sum and Outlier， radial MR， the MR-Egger intercept method， and the Cochrane Q test were used for sensitivity analysis. Results The univariate MR analysis revealed a bidirectional causal relationship between NAFLD and T2DM in the general population （forward analysis： odds ratio ［OR］=9.75， 95% confidence interval ［CI］： 2.57‍ ‍—‍ ‍37.00， P<0.001； reverse analysis： OR=1.01， 95%CI： 1.00‍ ‍—‍ ‍1.01， P<0.01）. After adjustment for BMI， the multivariate MR analysis showed that the causal relationship between NAFLD and T2DM remained significant in the general population （OR=33.12， 95%CI： 7.57‍ ‍—‍ ‍144.95， P<0.000 1）. The subgroup analysis showed a causal relationship between NAFLD and T2DM across all BMI subtypes （lean subgroup： OR=12.19， 95%CI： 3.35‍ ‍—‍ ‍44.40， P<0.001； overweight subgroup： OR=4.30， 95%CI： 1.69‍ ‍—‍ ‍10.92， P<0.01； obese subgroup： OR=1.67， 95%CI： 1.14‍ ‍—‍ ‍2.44， P<0.01）. Conclusion This study reveals the causal relationship between NAFLD and T2DM in the general population of NAFLD and across different BMI subtypes from a genetic perspective.
- Non-alcoholic Fatty Liver Disease,
- Diabetes Mellitus， Type 2,
- Body Mass Index,
- Mendelian Randomization Analysis

FullText(HTML)

References(49)

References

[1]	POWELL EE, WONG VWS, RINELLA M. Non-alcoholic fatty liver disease[J]. Lancet, 2021, 397( 10290): 2212- 2224. DOI: 10.1016/S0140-6736(20)32511-3.
[2]	RIAZI K, AZHARI H, CHARETTE JH, et al. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2022, 7( 9): 851- 861. DOI: 10.1016/S2468-1253(22)00165-0.
[3]	LI L, LIU DW, YAN HY, et al. Obesity is an independent risk factor for non-alcoholic fatty liver disease: Evidence from a meta-analysis of 21 cohort studies[J]. Obes Rev, 2016, 17( 6): 510- 519. DOI: 10.1111/obr.12407.
[4]	NABI O, LAPIDUS N, BOURSIER J, et al. Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes(NASH-CO Study)[J]. Hepatology, 2023, 78( 1): 272- 283. DOI: 10.1097/HEP.0000000000000329.
[5]	XU R, PAN J, ZHOU W, et al. Recent advances in lean NAFLD[J]. Biomed Pharmacother, 2022, 153: 113331. DOI: 10.1016/j.biopha.2022.113331.
[6]	TANG A, NG CH, PHANG PH, et al. Comparative burden of metabolic dysfunction in lean NAFLD vs non-lean NAFLD-A systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2023, 21( 7): 1750- 1760. e 12. DOI: 10.1016/j.cgh.2022.06.029.
[7]	International Diabetes Federation. IDF Diabetes Atlas(10th ed)[M]. Brussels: International Diabetes Federation, 2022.
[8]	YOUNOSSI ZM, GOLABI P, PRICE JK, et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes[J]. Clin Gastroenterol Hepatol, 2024. DOI: 10.1016/j.cgh.2024.03.006.[ Online ahead of print]
[9]	CAO LM, AN Y, LIU HY, et al. Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: A systematic review and meta-analysis[J]. BMC Med, 2024, 22( 1): 101. DOI: 10.1186/s12916-024-03315-0.
[10]	GAO YT, ZHAO TY, SONG SN, et al. Lean nonalcoholic fatty liver disease and risk of incident type 2 diabetes mellitus: A literature review and meta-analysis[J]. Diabetes Res Clin Pract, 2023, 200: 110699. DOI: 10.1016/j.diabres.2023.110699.
[11]	BYRNE CD, TARGHER G. NAFLD: A multisystem disease[J]. J Hepatol, 2015, 62( 1 suppl): S47- S64. DOI: 10.1016/j.jhep.2014.12.012.
[12]	SEKULA P, FABIOLA GRECO M, PATTARO C, et al. Mendelian randomization as an approach to assess causality using observational data[J]. J Am Soc Nephrol, 2016, 27( 11): 3253- 3265. DOI: 10.1681/ASN.2016010098.
[13]	FERENCE BA, HOLMES MV, SMITH GD. Using Mendelian randomization to improve the design of randomized trials[J]. Cold Spring Harb Perspect Med, 2021, 11( 7): a040980. DOI: 10.1101/cshperspect.a040980.
[14]	SKRIVANKOVA VW, RICHMOND RC, WOOLF BAR, et al. Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: The STROBE-MR statement[J]. JAMA, 2021, 326( 16): 1614- 1621. DOI: 10.1001/jama.2021.18236.
[15]	SUN ZW, PAN XC, TIAN AW, et al. Genetic variants in HFE are associated with non-alcoholic fatty liver disease in lean individuals[J]. JHEP Rep, 2023, 5( 7): 100744. DOI: 10.1016/j.jhepr.2023.100744.
[16]	O’CONNOR MJ, SCHROEDER P, HUERTA-CHAGOYA A, et al. Recessive genome-wide meta-analysis illuminates genetic architecture of type 2 diabetes[J]. Diabetes, 2022, 71( 3): 554- 565. DOI: 10.2337/db21-0545.
[17]	YENGO L, SIDORENKO J, KEMPER KE, et al. Meta-analysis of genome-wide association studies for height and body mass index in ∼700000 individuals of European ancestry[J]. Hum Mol Genet, 2018, 27( 20): 3641- 3649. DOI: 10.1093/hmg/ddy271.
[18]	HEMANI G, TILLING K, DAVEY SMITH G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data[J]. PLoS Genet, 2017, 13( 11): e1007081. DOI: 10.1371/journal.pgen.1007081.
[19]	BURGESS S, SCOTT RA, TIMPSON NJ, et al. Using published data in Mendelian randomization: A blueprint for efficient identification of causal risk factors[J]. Eur J Epidemiol, 2015, 30( 7): 543- 552. DOI: 10.1007/s10654-015-0011-z.
[20]	BOWDEN J, DAVEY SMITH G, BURGESS S. Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression[J]. Int J Epidemiol, 2015, 44( 2): 512- 525. DOI: 10.1093/ije/dyv080.
[21]	XUE HR, SHEN XT, PAN W. Constrained maximum likelihood-based Mendelian randomization robust to both correlated and uncorrelated pleiotropic effects[J]. Am J Hum Genet, 2021, 108( 7): 1251- 1269. DOI: 10.1016/j.ajhg.2021.05.014.
[22]	BOWDEN J, DAVEY SMITH G, HAYCOCK PC, et al. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted Median estimator[J]. Genet Epidemiol, 2016, 40( 4): 304- 314. DOI: 10.1002/gepi.21965.
[23]	SANDERSON E, DAVEY SMITH G, WINDMEIJER F, et al. An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings[J]. Int J Epidemiol, 2019, 48( 3): 713- 727. DOI: 10.1093/ije/dyy262.
[24]	BURGESS S, THOMPSON SG. Interpreting findings from Mendelian randomization using the MR-Egger method[J]. Eur J Epidemiol, 2017, 32( 5): 377- 389. DOI: 10.1007/s10654-017-0255-x.
[25]	VERBANCK M, CHEN CY, NEALE B, et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases[J]. Nat Genet, 2018, 50( 5): 693- 698. DOI: 10.1038/s41588-018-0099-7.
[26]	BOWDEN J, SPILLER W, DEL GRECO M F, et al. Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression[J]. Int J Epidemiol, 2018, 47( 6): 2100. DOI: 10.1093/ije/dyy265.
[27]	BOWDEN J, DEL GRECO M F, MINELLI C, et al. Improving the accuracy of two-sample summary-data Mendelian randomization: Moving beyond the NOME assumption[J]. Int J Epidemiol, 2019, 48( 3): 728- 742. DOI: 10.1093/ije/dyy258.
[28]	BURGESS S, BOWDEN J, FALL T, et al. Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants[J]. Epidemiology, 2017, 28( 1): 30- 42. DOI: 10.1097/EDE.0000000000000559.
[29]	Fatty Liver and Alcoholic Liver Disease Group, Hepatology Branch of Chinese Medical Association. Guidelines for diagnosis and treatment of nonalcoholic fatty liver diseases[J]. J Clin Hepatol, 2010, 2( 4): 43- 48. DOI: 10.3969/j.issn.1674-7380.2010.04.013. 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南[J]. 临床肝胆病杂志, 2010, 26( 2): 120- 124. DOI: 10.3760/cma.j.jssn.1674-5809.2010.01.000.
[30]	LIU ZP, ZHANG Y, GRAHAM S, et al. Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping[J]. J Hepatol, 2020, 73( 2): 263- 276. DOI: 10.1016/j.jhep.2020.03.006.
[31]	NI XT, TONG C, HALENGBIEKE A, et al. Association between nonalcoholic fatty liver disease and type 2 diabetes: A bidirectional two-sample Mendelian randomization study[J]. Diabetes Res Clin Pract, 2023, 206: 110993. DOI: 10.1016/j.diabres.2023.110993.
[32]	MANTOVANI A, BYRNE CD, BONORA E, et al. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: A meta-analysis[J]. Diabetes Care, 2018, 41( 2): 372- 382. DOI: 10.2337/dc17-1902.
[33]	MANTOVANI A, PETRACCA G, BEATRICE G, et al. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: An updated meta-analysis of 501 022 adult individuals[J]. Gut, 2021, 70( 5): 962- 969. DOI: 10.1136/gutjnl-2020-322572.
[34]	KOSMALSKI M, ŚLIWIŃSKA A, DRZEWOSKI J. Non-alcoholic fatty liver disease or type 2 diabetes mellitus-the chicken or the egg dilemma[J]. Biomedicines, 2023, 11( 4): 1097. DOI: 10.3390/biomedicines11041097.
[35]	KHAN RS, BRIL F, CUSI K, et al. Modulation of insulin resistance in nonalcoholic fatty liver disease[J]. Hepatology, 2019, 70( 2): 711- 724. DOI: 10.1002/hep.30429.
[36]	ZHANG XY, LIU Y, WANG WL, et al. Diagnosis and evaluation of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2023, 39( 8): 1780- 1788. DOI: 10.3969/j.issn.1001-5256.2023.08.003. 张馨元, 刘宇, 王文玲, 等. 非酒精性脂肪性肝病的诊断与评估[J]. 临床肝胆病杂志, 2023, 39( 8): 1780- 1788. DOI: 10.3969/j.issn.1001-5256.2023.08.003.
[37]	ESLAM M, VALENTI L, ROMEO S. Genetics and epigenetics of NAFLD and NASH: Clinical impact[J]. J Hepatol, 2018, 68( 2): 268- 279. DOI: 10.1016/j.jhep.2017.09.003.
[38]	LIU DJ, PELOSO GM, YU HJ, et al. Exome-wide association study of plasma lipids in>300, 000 individuals[J]. Nat Genet, 2017, 49( 12): 1758- 1766. DOI: 10.1038/ng.3977.
[39]	BESSONE F, RAZORI MV, ROMA MG. Molecular pathways of nonalcoholic fatty liver disease development and progression[J]. Cell Mol Life Sci, 2019, 76( 1): 99- 128. DOI: 10.1007/s00018-018-2947-0.
[40]	MALONE JI, HANSEN BC. Does obesity cause type 2 diabetes mellitus(T2DM)? Or is it the opposite?[J]. Pediatr Diabetes, 2019, 20( 1): 5- 9. DOI: 10.1111/pedi.12787.
[41]	YE Q, ZOU BY, YEO YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2020, 5( 8): 739- 752. DOI: 10.1016/S2468-1253(20)30077-7.
[42]	PINGITORE P, ROMEO S. The role of PNPLA3 in health and disease[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2019, 1864( 6): 900- 906. DOI: 10.1016/j.bbalip.2018.06.018.
[43]	ZHANG YJ, ZHOU XQ. Research advances in lean nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2023, 39( 12): 2914- 2919. DOI: 10.3969/j.issn.1001-5256.2023.12.024. 张瑜娟, 周希乔. 瘦型非酒精性脂肪性肝病的研究进展[J]. 临床肝胆病杂志, 2023, 39( 12): 2914- 2919. DOI: 10.3969/j.issn.1001-5256.2023.12.024.
[44]	SMITH GI, POLIDORI DC, YOSHINO M, et al. Influence of adiposity, insulin resistance, and intrahepatic triglyceride content on insulin kinetics[J]. J Clin Invest, 2020, 130( 6): 3305- 3314. DOI: 10.1172/JCI136756.
[45]	TOBARI M, HASHIMOTO E, TANIAI M, et al. Characteristics of non-alcoholic steatohepatitis among lean patients in Japan: Not uncommon and not always benign[J]. J Gastroenterol Hepatol, 2019, 34( 8): 1404- 1410. DOI: 10.1111/jgh.14585.
[46]	PETTA S, CIMINNISI S, DI MARCO V, et al. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2017, 45( 4): 510- 518. DOI: 10.1111/apt.13889.
[47]	ZHOU XM, YU XY, SONG ZY. Clinical characteristics and management of lean nonalcoholic fatty liver disease[J]. Chin J Health Manag, 2024, 18( 3): 236- 240. DOI: 10.3760/cma.j.cn115624-20230803-00047. 周馨媚, 余馨妍, 宋震亚. 瘦型非酒精性脂肪性肝病的临床特点和管理[J]. 中华健康管理学杂志, 2024, 18( 3): 236- 240. DOI: 10.3760/cma.j.cn115624-20230803-00047.
[48]	LI N, XANG W, WU SL, et al. Association between the lean nonalcoholic fatty liver disease and risk of incident type 2 diabetes in a healthy population of Northwest China: A retrospective cohort study with a 2-year follow-up period[J]. Front Endocrinol, 2023, 14: 1173757. DOI: 10.3389/fendo.2023.1173757.
[49]	FRACANZANI AL, PETTA S, LOMBARDI R, et al. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity[J]. Clin Gastroenterol Hepatol, 2017, 15( 10): 1604- 1611. e 1. DOI: 10.1016/j.cgh.2017.04.045.

Relative Articles

[1]	Zaichun PU, Ping JIA, Juan LIU, Yushuang SU, Li WANG, Qin ZHANG, Danyang GUO. Risk prediction models for pancreatic fistula after pancreaticoduodenectomy： A systematic review and a Meta-analysis[J]. Journal of Clinical Hepatology, 2024, 40(11): 2266-2276. doi: 10.12449/JCH241121
[2]	Xin DAI, Hanlin LIU, Qiang WANG, Peng SHU, Long CHENG, Tao WANG. Short-term efficacy and safety of Da Vinci robotic pancreaticoduodenectomy versus traditional laparoscopic pancreaticoduodenectomy: A meta-analysis[J]. Journal of Clinical Hepatology, 2022, 38(5): 1106-1113. doi: 10.3969/j.issn.1001-5256.2022.05.025
[3]	Lin ZHU, Xiaoli YANG, Li LIU, Lanting XU, Yuanhong LENG, Jing CHEN. Efficacy and safety of enhanced recovery after surgery in the perioperative period of pancreaticoduodenectomy: A systematic review and Meta-analysis[J]. Journal of Clinical Hepatology, 2022, 38(6): 1356-1363. doi: 10.3969/j.issn.1001-5256.2022.06.026
[4]	Ying LI, Ping LIANG. Effect of thymosin a1 on complications after laparoscopic pancreaticoduodenectomy in elderly patients[J]. Journal of Clinical Hepatology, 2021, 37(8): 1894-1897. doi: 10.3969/j.issn.1001-5256.2021.08.028
[5]	Sijie YANG, Hui ZHANG, Zhengfeng WANG, Zhilong SHI, Wence ZHOU. Effect of Braun anastomosis on delayed gastric emptying after pancreaticoduodenectomy[J]. Journal of Clinical Hepatology, 2021, 37(7): 1652-1656. doi: 10.3969/j.issn.1001-5256.2021.07.034
[6]	Li ChangXu, Yuan JingJing, Wang ShouQian, Tang ChaoHui, Xu LuYao, Wang YingChao. Clinical effect of artery-first approach versus traditional approach for pancreaticoduodenectomy:A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(8): 1805-1810. doi: 10.3969/j.issn.1001-5256.2020.08.025
[7]	Yu PeiHe, Su Song, Chen Shi, Wang JinCheng, Chen XinPei, Luo De. Clinical effect of pancreaticoduodenectomy with total mesopancreas excision versus traditional pancreaticoduodenectomy in treatment of pancreatic head carcinoma and periampullary cancer:A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(8): 1811-1815. doi: 10.3969/j.issn.1001-5256.2020.08.026
[8]	Ji Bo, Liu SongYang, Zhang Wei, Wang YingChao, Liu YaHui. Clinical effect of the enhanced recovery after surgery strategy for pancreaticoduodenectomy[J]. Journal of Clinical Hepatology, 2019, 35(5): 1032-1036. doi: 10.3969/j.issn.1001-5256.2019.05.019
[9]	Ren Long, Zhang Miao, Zhang Yun. Application of enhanced recovery after surgery in perioperative period of hepatectomy: a Meta-analysis[J]. Journal of Clinical Hepatology, 2018, 34(3): 573-578. doi: 10.3969/j.issn.1001-5256.2018.03.025
[10]	Zhang BaoHua, Yang Ya, Gong JianPing. Clinical effect and safety of nutritional support after pancreaticoduodenectomy: A Meta-analysis[J]. Journal of Clinical Hepatology, 2018, 34(6): 1231-1236. doi: 10.3969/j.issn.1001-5256.2018.06.020
[11]	Hu YaNan, Yang GuiYuan, Qian ZhuYin, Yang XiaoJun. An excerpt of pancreatic anastomosis after pancreatoduodenectomy: a position statement by the International Study Group of Pancreatic Surgery (2016)[J]. Journal of Clinical Hepatology, 2017, 33(4): 627-631. doi: 10.3969/j.issn.1001-5256.2017.04.005
[12]	Wang XiaoLong, Tu YanYuan, Wang Wei, Yuan ZuRong, Tang JianXiong, Tang WenHao, Wang WeiYi. Risk factors for pancreatic fistula after pancreaticoduodenectomy[J]. Journal of Clinical Hepatology, 2017, 33(1): 116-120. doi: 10.3969/j.issn.1001-5256.2017.01.025
[13]	He XueRong, Zhang BaoHua, Gong JianPing. Effect of preoperative biliary drainage on complications and short-term mortality after pancreaticoduodenectomy: a Meta-analysis[J]. Journal of Clinical Hepatology, 2017, 33(9): 1749-1753. doi: 10.3969/j.issn.1001-5256.2017.09.024
[14]	Li WeiNan, Yang Gang, Li JingDong, Tang Tao, Li Qiang, Li Yong. Safety of fast track surgery in pancreaticoduodenectomy: a Meta-analysis[J]. Journal of Clinical Hepatology, 2017, 33(1): 121-125. doi: 10.3969/j.issn.1001-5256.2017.01.026
[15]	Pan Chao, Xi PengCheng, Shi ZuoLiang, Bian JianMin, Yang KunXing, Liu ZiJun, Ni ShaoZhong, Yang ShiYong, Shi KaiWang. Effect of Blumgart anastomosis in prevention and treatment of pancreatic fistula after pancreaticoduodenectomy[J]. Journal of Clinical Hepatology, 2016, 32(2): 333-336. doi: 10.3969/j.issn.1001-5256.2016.02.028
[16]	Lin Yang, Wei Wei, Zhang XiaoHui, Wu KangJian, Han Chao, Xu LiJian. Postoperative complications of laparoscopic versus open common hepatic duct-jejunal Roux-en-Y anastomosis: a Meta-analysis[J]. Journal of Clinical Hepatology, 2016, 32(10): 1959-1963. doi: 10.3969/j.issn.1001-5256.2016.10.029
[17]	Xing GuoQuan, Yan TianQing, Jia ZhiShuo, Kang TieLi. Risk factors for pancreatic fistula after pancreaticoduodenectomy and its prevention and treatment measures [J]. Journal of Clinical Hepatology, 2015, 31(12): 2110-2113. doi: 10.3969/j.issn.1001-5256.2015.12.029
[18]	Li QiNan, Zhang YuHuai, Geng Jie. Safety and efficacy of fast-track surgery in perioperative nursing for biliary calculi surgery: a meta-analysis[J]. Journal of Clinical Hepatology, 2015, 31(10): 1660-1664. doi: 10.3969/j.issn.1001-5256.2015.10.025
[19]	Pan Fan, Jiang Yi, Zhang XiaoJin, Pan Chen. Risk factors of pancreatic fistula after pancreaticoduodenectomy[J]. Journal of Clinical Hepatology, 2012, 28(8): 587-588+602.
[20]	Li JunJie, Li Xiao, Yue ShuQiang. Analysis of high risks of postoperative pancreaticojejunostomy leakage and its treatment[J]. Journal of Clinical Hepatology, 2011, 27(11): 1213-1218.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(5) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (430) PDF downloads(37)

The genetic association between nonalcoholic fatty liver disease and type 2 diabetes mellitus in different body mass index categories： A bidirectional Mendelian randomization study

DOI: 10.12449/JCH241011

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

The genetic association between nonalcoholic fatty liver disease and type 2 diabetes mellitus in different body mass index categories： A bidirectional Mendelian randomization study

DOI: 10.12449/JCH241011

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content